Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carbamazepine effect on Tepotinib PK
NCT05213481Phase 1Completed
- Sponsor
- Merck KGaA
- Start
- Dec 2021
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tepotinib in non-small cell lung cancer (NSCLC), sponsored by Merck KGaA. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity, Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Measurable Concentration and 1 more. Started Dec 2021; status: completed.
02
Drugs
tepotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05213481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05213481.